BIOMAT Database Logo BIOMAT Database Logo

Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents. 1996

Y Hsiung, and M Jannatipour, and A Rose, and J McMahon, and D Duncan, and J L Nitiss
Division of Hematology/Oncology, Childrens Hospital, Los Angeles, California 90027, USA.

DNA topoisomerase II is the target of a variety of important antitumor agents, including etoposide, adriamycin, and amsacrine. We have constructed a system for analyzing the action of anti-topoisomerase II agents using the yeast Saccharomyces cerevisiae and have constructed vectors for expressing human topoisomerase II functionally in yeast. We have demonstrated that temperature-conditional yeast TOP2 mutants can be complemented by expression of wild-type human topoisomerase II alpha. Furthermore, expression of human topoisomerase II in yeast results in a quantitatively unique pattern of sensitivity to amsacrine. We also have constructed mutations in human TOP2 based on previously identified mutations from a human cell line selected for resistance to teniposide. Our experiments demonstrate that mutation of either arginine 450 or proline 803 of human topoisomerase II can result in an enzyme that has altered sensitivity to anti-topoisomerase II agents, and that a human enzyme carrying both mutations confers a higher level of drug resistance than enzymes carrying either single mutation.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000483 Alleles Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product. Allelomorphs,Allele,Allelomorph
D000677 Amsacrine An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent. m-AMSA,AMSA,AMSA P-D,Amsacrina,Amsidine,Amsidyl,Cain's Acridine,NSC-141549,NSC-156303,NSC-249992,SN-11841,SN11841,meta-AMSA,AMSA P D,AMSA PD,Cain Acridine,Cains Acridine,NSC 141549,NSC 156303,NSC 249992,NSC141549,NSC156303,NSC249992,SN 11841,meta AMSA
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001120 Arginine An essential amino acid that is physiologically active in the L-form. Arginine Hydrochloride,Arginine, L-Isomer,DL-Arginine Acetate, Monohydrate,L-Arginine,Arginine, L Isomer,DL Arginine Acetate, Monohydrate,Hydrochloride, Arginine,L Arginine,L-Isomer Arginine,Monohydrate DL-Arginine Acetate
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA

Related Publications

Y Hsiung, and M Jannatipour, and A Rose, and J McMahon, and D Duncan, and J L Nitiss
Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.
August 1999, Biochemistry,
Y Hsiung, and M Jannatipour, and A Rose, and J McMahon, and D Duncan, and J L Nitiss
DNA topoisomerase II mutations and resistance to anti-tumor drugs.
September 1995, BioEssays : news and reviews in molecular, cellular and developmental biology,
Y Hsiung, and M Jannatipour, and A Rose, and J McMahon, and D Duncan, and J L Nitiss
Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells.
April 2000, Molecular pharmacology,
Y Hsiung, and M Jannatipour, and A Rose, and J McMahon, and D Duncan, and J L Nitiss
Diketones as photosensitizing agents: application to alpha-amino acids and enzymes.
May 1982, Photochemistry and photobiology,
Y Hsiung, and M Jannatipour, and A Rose, and J McMahon, and D Duncan, and J L Nitiss
Mutations in the IGF-II pathway that confer resistance to lytic reovirus infection.
August 2004, BMC cell biology,
Y Hsiung, and M Jannatipour, and A Rose, and J McMahon, and D Duncan, and J L Nitiss
Yeast systems for demonstrating the targets of anti-topoisomerase II agents.
January 2001, Methods in molecular biology (Clifton, N.J.),
Y Hsiung, and M Jannatipour, and A Rose, and J McMahon, and D Duncan, and J L Nitiss
Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir.
July 2004, Journal of virology,
Y Hsiung, and M Jannatipour, and A Rose, and J McMahon, and D Duncan, and J L Nitiss
Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents.
December 1992, Journal of virology,
Y Hsiung, and M Jannatipour, and A Rose, and J McMahon, and D Duncan, and J L Nitiss
Genetic interactions among Chlamydomonas reinhardtii mutations that confer resistance to anti-microtubule herbicides.
February 1992, Genetics,
Y Hsiung, and M Jannatipour, and A Rose, and J McMahon, and D Duncan, and J L Nitiss
Mutations in alpha-tubulin confer dinitroaniline resistance at a cost to microtubule function.
December 2007, Molecular biology of the cell,
Copied contents to your clipboard!